Here's What Key Metrics Tell Us About Agilon (AGL) Q2 Earnings

Agilon Health (AGL) reported Q2 2025 revenue of $1.39 billion, a 5.9% year-over-year decline that missed the $1.47 billion consensus estimate. The company posted an EPS of -$0.25, significantly below the -$0.07 from a year prior and the -$0.11 consensus. Despite exceeding estimates for average Medicare Advantage members, these financial misses have contributed to a 30% decline in AGL's stock over the past month, sharply underperforming the S&P 500.

Analysis

Agilon Health's (AGL) second-quarter 2025 results reveal a significant deterioration in financial performance, triggering a severe negative market reaction. The company reported revenue of $1.39 billion, a 5.9% year-over-year decline and a 4.98% miss against the Zacks Consensus Estimate of $1.47 billion. Profitability worsened considerably, with an EPS of -$0.25, a stark contrast to the -$0.07 reported in the prior-year quarter and a substantial 127.27% miss versus the -$0.11 consensus estimate. This underperformance stems from its core Medical Services segment, which also saw revenue fall 5.9% to $1.39 billion, missing analyst expectations. A critical disconnect emerges when comparing these financial results to operational metrics; the company exceeded expectations for its Average Medicare Advantage Members, which grew to 498,000 against an estimate of 493,100. This juxtaposition suggests that while Agilon is succeeding in expanding its member base, it is failing to translate this growth into revenue and is facing escalating costs or margin pressures. The market's response has been punitive, with the stock plunging 30% over the past month, drastically underperforming the S&P 500 composite's modest 0.6% gain.

Key Decisions for Investors

• Investors should scrutinize the clear disconnect between the growth in Medicare Advantage members and the decline in revenue and earnings, as this indicates potential systemic issues in monetization strategy or cost control.
• Given the stock's 30% decline, a key consideration is whether the overwhelmingly negative Q2 results are now fully priced in, a possibility supported by the neutral Zacks Rank #3 (Hold) rating.
• It is critical to monitor future quarters for evidence that management can reverse the negative revenue trend and demonstrate a clear path to profitability before initiating or adding to long positions.